DK2068874T3 - Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer - Google Patents
Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer Download PDFInfo
- Publication number
- DK2068874T3 DK2068874T3 DK07840746T DK07840746T DK2068874T3 DK 2068874 T3 DK2068874 T3 DK 2068874T3 DK 07840746 T DK07840746 T DK 07840746T DK 07840746 T DK07840746 T DK 07840746T DK 2068874 T3 DK2068874 T3 DK 2068874T3
- Authority
- DK
- Denmark
- Prior art keywords
- myelomes
- antibodies
- methods
- combination therapy
- therapy based
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83618506P | 2006-08-07 | 2006-08-07 | |
| US94426207P | 2007-06-15 | 2007-06-15 | |
| PCT/US2007/075403 WO2008019378A1 (en) | 2006-08-07 | 2007-08-07 | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2068874T3 true DK2068874T3 (da) | 2015-04-27 |
Family
ID=38831279
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07840746T DK2068874T3 (da) | 2006-08-07 | 2007-08-07 | Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer |
| DK13168383.1T DK2641601T3 (en) | 2006-08-07 | 2007-08-07 | Methods for treating multiple myeloma using the combination therapy based on HuLuc63 with bortezomib |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13168383.1T DK2641601T3 (en) | 2006-08-07 | 2007-08-07 | Methods for treating multiple myeloma using the combination therapy based on HuLuc63 with bortezomib |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US8632772B2 (enExample) |
| EP (5) | EP2942057A1 (enExample) |
| JP (1) | JP5340935B2 (enExample) |
| CN (1) | CN101686971B (enExample) |
| AU (1) | AU2007281684C1 (enExample) |
| BR (1) | BRPI0716647A2 (enExample) |
| CA (1) | CA2660356C (enExample) |
| CY (5) | CY1116247T1 (enExample) |
| DK (2) | DK2068874T3 (enExample) |
| ES (2) | ES2535437T3 (enExample) |
| HR (2) | HRP20150449T1 (enExample) |
| HU (4) | HUE029027T2 (enExample) |
| IL (2) | IL196919A (enExample) |
| LT (4) | LT2641601T (enExample) |
| LU (3) | LU93277I2 (enExample) |
| MX (1) | MX2009001441A (enExample) |
| NL (1) | NL300840I2 (enExample) |
| NO (1) | NO346835B1 (enExample) |
| NZ (1) | NZ574978A (enExample) |
| PL (2) | PL2641601T3 (enExample) |
| PT (2) | PT2641601T (enExample) |
| SI (2) | SI2641601T1 (enExample) |
| WO (1) | WO2008019378A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842293B2 (en) * | 2006-08-07 | 2010-11-30 | Facet Biotech Corporation | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
| EP2942057A1 (en) | 2006-08-07 | 2015-11-11 | AbbVie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| EP2300034B1 (en) * | 2008-06-02 | 2018-08-08 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical composition for use in treating or preventing multiple myeloma or waldenstrom's macroglobulinemia |
| CA2727278A1 (en) | 2008-06-16 | 2010-01-21 | Immunogen, Inc. | Novel synergistic effects |
| AU2009308516B2 (en) * | 2008-10-21 | 2016-08-25 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| ES2502541T3 (es) | 2009-09-10 | 2014-10-03 | Kyowa Hakko Kirin Co., Ltd. | Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4) |
| CA2780998C (en) * | 2009-11-24 | 2016-07-12 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
| CN102241773B (zh) * | 2010-05-13 | 2014-05-14 | 四川大学 | 抗骨髓瘤细胞多克隆抗体及其制备方法 |
| CA2888803A1 (en) | 2012-11-05 | 2014-05-08 | Jooeun Bae | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| EP3066128B1 (en) * | 2013-11-06 | 2018-10-31 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| WO2015069703A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| JP2017504566A (ja) * | 2013-11-21 | 2017-02-09 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗アルファ−シヌクレイン抗体及び使用方法 |
| HUE061382T2 (hu) | 2014-08-22 | 2023-06-28 | Celgene Corp | Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva |
| WO2016049022A1 (en) * | 2014-09-23 | 2016-03-31 | Board Of Trustees Of Michigan State University | Compositions and methods for modulating an immune response |
| WO2016054354A1 (en) | 2014-10-02 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
| ES2832711T3 (es) | 2014-10-31 | 2021-06-11 | Abbvie Biotherapeutics Inc | Anticuerpos anti-CS1 y conjugados anticuerpo fármaco |
| US10302644B2 (en) | 2014-11-04 | 2019-05-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
| KR20170088984A (ko) * | 2014-12-04 | 2017-08-02 | 브리스톨-마이어스 스큅 컴퍼니 | 암 (골수종)을 치료하기 위한 항-cs1 항체와 항-pd1 항체의 조합 |
| RS61668B1 (sr) | 2015-05-13 | 2021-04-29 | Morphosys Ag | Lečenje multiplog mijeloma (mm) |
| BR112017027692A2 (pt) * | 2015-06-29 | 2018-10-09 | Bristol Myers Squibb Co | regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do câncer |
| CN105688185B (zh) * | 2016-03-13 | 2019-03-19 | 浙江药苑生物科技有限公司 | 一种用于治疗骨髓增生、骨癌的药物组合物及其用途 |
| US11124579B2 (en) | 2017-03-29 | 2021-09-21 | Agency For Science, Technology And Research | Anti oligosaccharide antibody |
| KR20200090193A (ko) * | 2017-11-22 | 2020-07-28 | 힐스트림 바이오파마 인크. | 보르테조밉을 포함하는 중합체 나노입자 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| US20220390455A1 (en) | 2019-11-05 | 2022-12-08 | Bristol-Myers Squibb Company | M-protein assays and uses thereof |
| CN115368462A (zh) * | 2022-07-19 | 2022-11-22 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112969A (en) | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| AU5930396A (en) | 1995-05-25 | 1996-12-11 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| ES2340027T3 (es) * | 2002-05-17 | 2010-05-28 | Celgene Corporation | Combinaciones para tratar el mieloma multiple. |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| EP1824513A4 (en) * | 2004-11-04 | 2010-06-09 | Fibron Ltd | TREATMENT OF B-CELL TUMORS |
| EP2942057A1 (en) | 2006-08-07 | 2015-11-11 | AbbVie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| US20080095768A1 (en) | 2006-08-07 | 2008-04-24 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| US7842293B2 (en) | 2006-08-07 | 2010-11-30 | Facet Biotech Corporation | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
-
2007
- 2007-08-07 EP EP15152731.4A patent/EP2942057A1/en not_active Withdrawn
- 2007-08-07 ES ES07840746.7T patent/ES2535437T3/es active Active
- 2007-08-07 WO PCT/US2007/075403 patent/WO2008019378A1/en not_active Ceased
- 2007-08-07 CA CA2660356A patent/CA2660356C/en active Active
- 2007-08-07 CN CN200780033988XA patent/CN101686971B/zh active Active
- 2007-08-07 SI SI200731803A patent/SI2641601T1/sl unknown
- 2007-08-07 NZ NZ574978A patent/NZ574978A/xx unknown
- 2007-08-07 JP JP2009523968A patent/JP5340935B2/ja active Active
- 2007-08-07 PT PT131683831T patent/PT2641601T/pt unknown
- 2007-08-07 EP EP16169025.0A patent/EP3115049A1/en not_active Withdrawn
- 2007-08-07 ES ES13168383.1T patent/ES2589302T3/es active Active
- 2007-08-07 EP EP07840746.7A patent/EP2068874B1/en active Active
- 2007-08-07 SI SI200731641T patent/SI2068874T1/sl unknown
- 2007-08-07 PL PL13168383T patent/PL2641601T3/pl unknown
- 2007-08-07 US US11/835,257 patent/US8632772B2/en active Active
- 2007-08-07 EP EP13168383.1A patent/EP2641601B8/en active Active
- 2007-08-07 EP EP13168364.1A patent/EP2641600A1/en not_active Withdrawn
- 2007-08-07 NO NO20090968A patent/NO346835B1/no unknown
- 2007-08-07 HU HUE13168383A patent/HUE029027T2/en unknown
- 2007-08-07 DK DK07840746T patent/DK2068874T3/da active
- 2007-08-07 PL PL07840746T patent/PL2068874T3/pl unknown
- 2007-08-07 LT LTEP13168383.1T patent/LT2641601T/lt unknown
- 2007-08-07 PT PT78407467T patent/PT2068874E/pt unknown
- 2007-08-07 DK DK13168383.1T patent/DK2641601T3/en active
- 2007-08-07 HR HRP20150449TT patent/HRP20150449T1/hr unknown
- 2007-08-07 MX MX2009001441A patent/MX2009001441A/es active IP Right Grant
- 2007-08-07 BR BRPI0716647A patent/BRPI0716647A2/pt not_active Application Discontinuation
- 2007-08-07 AU AU2007281684A patent/AU2007281684C1/en active Active
-
2009
- 2009-02-05 IL IL196919A patent/IL196919A/en active Protection Beyond IP Right Term
-
2013
- 2013-12-23 US US14/139,096 patent/US20140322201A1/en not_active Abandoned
-
2015
- 2015-04-24 CY CY20151100379T patent/CY1116247T1/el unknown
- 2015-08-24 US US14/834,077 patent/US20160137735A1/en not_active Abandoned
-
2016
- 2016-02-03 IL IL243933A patent/IL243933A0/en unknown
- 2016-08-18 CY CY20161100817T patent/CY1117992T1/el unknown
- 2016-10-06 HR HRP20161284TT patent/HRP20161284T1/hr unknown
- 2016-10-20 HU HUS1600044C patent/HUS1600044I1/hu unknown
- 2016-10-20 HU HUS1600043C patent/HUS1600043I1/hu unknown
- 2016-10-20 HU HUS1600045C patent/HUS1600045I1/hu unknown
- 2016-10-24 LU LU93277C patent/LU93277I2/fr unknown
- 2016-10-24 LU LU93276C patent/LU93276I2/fr unknown
- 2016-10-24 LU LU93275C patent/LU93275I2/fr unknown
- 2016-10-25 NL NL300840C patent/NL300840I2/nl unknown
- 2016-10-26 CY CY2016038C patent/CY2016038I1/el unknown
- 2016-10-26 CY CY2016036C patent/CY2016036I1/el unknown
- 2016-10-26 CY CY2016037C patent/CY2016037I1/el unknown
- 2016-10-27 LT LTPA2016029C patent/LTPA2016029I1/lt unknown
- 2016-10-27 LT LTPA2016031C patent/LTC2068874I2/lt unknown
- 2016-10-27 LT LTPA2016030C patent/LTPA2016030I1/lt unknown
-
2017
- 2017-08-07 US US15/670,681 patent/US20170342150A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2068874T3 (da) | Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer | |
| DK1874821T3 (da) | Kombination af antistoffer med glykokortikoider til behandling af kræft | |
| DK2101819T3 (da) | Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis | |
| DK2781593T3 (da) | Fremgangsmåde til behandling af methanemissioner | |
| DK2212070T3 (da) | Fremgangsmåde til behandling af træ | |
| DK1999225T3 (da) | Fremgangsmåder til behandling af borehuller med genanvendelige fluider | |
| DK1877232T3 (da) | Fremgangsmåde til behandling af træoverflader | |
| DK2545939T3 (da) | Tetrahydrobiopterin til behandling af tilstande associeret med forhøjede phenylalaninniveauer | |
| DK1874781T3 (da) | Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme | |
| DK2081669T3 (da) | Fremgangsmåde og anordning til fremstilling af granulater | |
| DK1986633T3 (da) | Behandling af duchennes muskeldystrofi | |
| DK2073811T3 (da) | Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme | |
| DK2293816T3 (da) | Fremgangsmåder til behandling af reumatoid arthritis | |
| DK2086944T3 (da) | Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater | |
| DK2001892T3 (da) | Imidazolthiazolforbindelser til behandling af proliferative sygdomme | |
| DK2034830T3 (da) | Anti-vla-1-antistof til behandling af slagtilfælde | |
| DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
| DK3403657T3 (da) | Anvendelse af oligouronater til behandling af slimhyperviskositet | |
| DK2164572T3 (da) | Carbamoyl-cyclohexaner til behandling af akut mani | |
| DK2012814T3 (da) | Fremgangsmåder til behandling af autoimmunsygdomme | |
| DK2117565T3 (da) | Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme | |
| DK2131841T3 (da) | Fremgangsmåder til behandling af akut smerte | |
| DK1982178T3 (da) | Fremgangsmåder til behandling af affektbetonede lidelser | |
| DK2044099T3 (da) | Fremgangsmåde til fremstillingen af s-fluormethyl-6,9-difluor-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-dien-17-carbothiat og mellemprodukter | |
| DK2323686T3 (da) | Adiponectin til behandling af lungesygdom |